Format

Send to

Choose Destination
Br J Clin Pharmacol. 2000 May;49(5):485-8.

A discordance of the cytochrome P450 2C19 genotype and phenotype in patients with advanced cancer.

Author information

1
Department of Pharmacology, Georgetown University Medical Center, 3900 Reservoir Road, NW, Washington, D.C., 20007, USA.

Abstract

AIMS:

To examine the relationship between cytochrome P450 2C19 (CYP2C19) genotype and expressed metabolic activity in 16 patients with advanced metastatic cancer.

METHODS:

Individual CYP2C19 genotypes were determined by PCR-based amplification, followed by restriction fragment length analysis, and compared with observed CYP2C19 metabolic activity, as determined using the log hydroxylation index of omeprazole.

RESULTS:

All 16 patients had an extensive metabolizer genotype. However, based on the antimode in a distribution of log omeprazole hydroxylation indices from healthy volunteers, four of the patients had a poor metabolizer phenotype and there was a general shift of the remaining 12 patients towards a slower metabolic phenotype. This suggests a reduction in metabolic activity for all patients relative to healthy volunteers. A careful analysis of patient medical records failed to reveal any drug interactions or other source for the observed discordance between genotype and phenotype.

CONCLUSIONS:

There are no previous reports of a 'discordance' between genotype and expressed enzyme activity in cancer patients. Such a decrease in enzyme activity could have an impact on the efficacy and toxicity of chemotherapeutic agents and other drugs, used in standard oncology practice.

PMID:
10792207
PMCID:
PMC2014949
DOI:
10.1046/j.1365-2125.2000.00189.x
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Wiley Icon for PubMed Central
Loading ...
Support Center